Black Diamond Therapeutics (BDTX) Net Income towards Common Stockholders: 2018-2021
Historic Net Income towards Common Stockholders for Black Diamond Therapeutics (BDTX) over the last 4 years, with Dec 2021 value amounting to -$123.4 million.
- Black Diamond Therapeutics' Net Income towards Common Stockholders fell 16.25% to -$25.5 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$111.6 million, marking a year-over-year decrease of 68.00%. This contributed to the annual value of -$123.4 million for FY2021, which is 88.32% down from last year.
- According to the latest figures from FY2021, Black Diamond Therapeutics' Net Income towards Common Stockholders is -$123.4 million, which was down 88.32% from -$65.5 million recorded in FY2020.
- Black Diamond Therapeutics' Net Income towards Common Stockholders' 5-year high stood at -$8.9 million during FY2018, with a 5-year trough of -$123.4 million in FY2021.
- For the 3-year period, Black Diamond Therapeutics' Net Income towards Common Stockholders averaged around -$72.6 million, with its median value being -$65.5 million (2020).
- Data for Black Diamond Therapeutics' Net Income towards Common Stockholders shows a maximum YoY slumped of 224.39% (in 2019) over the last 5 years.
- Over the past 4 years, Black Diamond Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$8.9 million in 2018, then slumped by 224.39% to -$28.9 million in 2019, then tumbled by 126.98% to -$65.5 million in 2020, then crashed by 88.32% to -$123.4 million in 2021.